
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics, Preclinical Pharmacology |
Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland [M. E. G., M. K., P. F., S. B., T. F.], and First Department of Surgery, Faculty of Medicine, Kagoshima University, Kagoshima, Japan [T. A.]
Purpose: Efficient adenovirus infection requires coxsackie-adenovirus receptor (CAR) and
v integrin. Whereas many malignant cells express these proteins poorly, normal tissues, especially liver, express high levels and are susceptible to adenovirus infection. Our previous studies showed that treatment of cancer cell lines with low concentrations of the histone deacetylase inhibitor FK228 (FR901228, depsipeptide), a drug in Phase II clinical trials, before infection was associated with an increase in adenovirus transgene expression. The purpose of these studies was to analyze the effects of FK228 on cultured normal human cells before initiating animal studies.
Experimental Design: Cancer and normal cells from the corresponding tissue were treated with FK228 and analyzed for the proteins needed for infection and the infection efficiency.
Results: Treatment of cancer cell lines with 1 ng/ml FK228 increased CAR RNA,
v integrin RNA, and histone H3 acetylation levels, and was associated with a 410-fold increase in the number of infected cells expressing the transgene. Similar treatment of normal human mammary epithelial cells, renal proximal tubule epithelial cells, and hepatocytes had little effect. The insensitivity of cultured normal cells may be explained, in part, by expression of the drug efflux pump P-glycoprotein, because addition of the P-glycoprotein inhibitor XR9576 (tariquidar) with FK228 resulted in increased histone acetylation and CAR expression.
Conclusion: These studies suggest that low concentrations of FK228 preferentially increase the efficiency of adenoviral transgene expression in cancer cells compared with cultured normal cells from the corresponding tissue and may increase the efficiency of adenovirus therapies in vivo.
This article has been cited by other articles:
![]() |
Y. Sasaki, H. Negishi, M. Idogawa, H. Suzuki, H. Mita, M. Toyota, Y. Shinomura, K. Imai, and T. Tokino Histone deacetylase inhibitor FK228 enhances adenovirus-mediated p53 family gene therapy in cancer models Mol. Cancer Ther., April 1, 2008; 7(4): 779 - 787. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Fan, J. Stanfield, Y. Guo, J. A. Karam, E. Frenkel, X. Sun, and J.-T. Hsieh Effect of Trans-2,3-Dimethoxycinnamoyl Azide on Enhancing Antitumor Activity of Romidepsin on Human Bladder Cancer Clin. Cancer Res., February 15, 2008; 14(4): 1200 - 1207. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Libertini, I. Iacuzzo, A. Ferraro, M. Vitale, M. Bifulco, A. Fusco, and G. Portella Lovastatin Enhances the Replication of the Oncolytic Adenovirus dl1520 and Its Antineoplastic Activity against Anaplastic Thyroid Carcinoma Cells Endocrinology, November 1, 2007; 148(11): 5186 - 5194. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. E. Goldsmith, A. Aguila, K. Steadman, A. Martinez, S. M. Steinberg, M. C. Alley, W. R. Waud, S. E. Bates, and T. Fojo The histone deacetylase inhibitor FK228 given prior to adenovirus infection can boost infection in melanoma xenograft model systems Mol. Cancer Ther., February 1, 2007; 6(2): 496 - 505. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Keriel, C. Rene, C. Galer, J. Zabner, and E. J. Kremer Canine Adenovirus Vectors for Lung-Directed Gene Transfer: Efficacy, Immune Response, and Duration of Transgene Expression Using Helper-Dependent Vectors J. Virol., February 1, 2006; 80(3): 1487 - 1496. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. D. Lacher, M. I. Tiirikainen, E. F. Saunier, C. Christian, M. Anders, M. Oft, A. Balmain, R. J. Akhurst, and W. M. Korn Transforming Growth Factor-{beta} Receptor Inhibition Enhances Adenoviral Infectability of Carcinoma Cells via Up-Regulation of Coxsackie and Adenovirus Receptor in Conjunction with Reversal of Epithelial-Mesenchymal Transition Cancer Res., February 1, 2006; 66(3): 1648 - 1657. [Abstract] [Full Text] [PDF] |
||||
![]() |
L.-C. Li, P. R. Carroll, and R. Dahiya Epigenetic Changes in Prostate Cancer: Implication for Diagnosis and Treatment J Natl Cancer Inst, January 19, 2005; 97(2): 103 - 115. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |